OlaparibFDA Approved: * December 19, 2014
Pharm Company: * ASTRAZENECA PHARMS
Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers. In December 2014, olaparib was approved for use as a single agent by the European Medicines Agenc... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.